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Summary
Background—Since influenza often presents non-specifically in infancy, we aimed to assess the 
extent to which existing respiratory surveillance platforms might underestimate the frequency of 
severe influenza disease among infants.
Methods—The Influenza and Respiratory Syncytial Virus in Infants (IRIS) study was a 
prospective observational study done at four hospitals in Albania, Jordan, Nicaragua, and the 
Philippines. We included acutely ill infants aged younger than 1 year admitted to hospital within 
10 days or less of illness onset during two influenza seasons (2015–16 and 2016–17) in Albania, 
Jordan, and Nicaragua, and over a continuous 34 week period (2015–16) in the Philippines. We 
assessed the frequency of influenza virus infections by real-time RT-PCR (rRT-PCR) and serology. 
The main study outcome was seroconversion, defined as convalescent antibody titres more than or 
equal to four-fold higher than acute sera antibody titres, and convalescent antibody titres of 40 or 
higher. Seroconverison was confirmed by haemagglutination inhibition assay for influenza A 
viruses, and by hemagglutination inhibition assay and microneutralisation for influenza B viruses.
Findings—Between June 27, 2015, and April 21, 2017, 3634 acutely ill infants were enrolled, of 
whom 1943 were enrolled during influenza seasons and had complete acute-convalescent pairs and 
thus were included in the final analytical sample. Of the 1943 infants, 94 (5%) were influenza-
positive by both rRT-PCR and serology, 58 (3%) were positive by rRT-PCR-only, and 102 (5%) 
were positive by serology only. Seroconversion to at least one of the influenza A or B viruses was 
observed among 196 (77%) of 254 influenza-positive infants. Of the 254 infants with influenza 
virus, 84 (33%) only had non-respiratory clinical discharge diagnoses (eg, sepsis, febrile seizures, 
dehydration, or other non-respiratory viral illness). A focus on respiratory diagnoses and rRT-
PCR-confirmed influenza underdetects influenza-associated hospital admissions among infants by 
a factor of 2·6 (95% CI 2·0–3·6). Findings were unchanged when syndromic severe acute 
respiratory infection criteria were applied instead of clinical diagnosis.
Interpretation—If the true incidence of laboratory-confirmed influenza-associated hospital 
admissions among infants is at least twice that of previous estimates, this substantially increases 
the global burden of severe influenza and expands our estimates of the preventive value of 
maternal and infant influenza vaccination programmes.
Funding—US Centers for Disease Control and Prevention.
Introduction
Although global rates of acute upper and lower respiratory disease are highest among infants 
aged younger than 1 year 1,2 and influenza virus infections are among the leading 
contributors to this burden,1–5 existing studies are likely to underestimate the frequency of 
influenza-associated hospital admissions in at least two ways. First, existing research and 
surveillance platforms, such as those focused on severe acute respiratory infections (SARI), 
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often overlook non-febrile and non-respiratory manifestations of influenza disease.6–8 
Second, since complications from influenza, such as pneumonia and bronchiolitis, often 
occur days after the primary infection, individuals might no longer be shedding influenza 
virus at the time of hospital admission.9–12 If substantial gaps in influenza diagnosis exist, 
the findings could be relevant to immunisation policy decisions, especially in low-income 
and middle-income countries (LMICs), where data about the potential preventive value of 
the influenza vaccine are scarce.13,14 Even in high-income countries, misperceptions about 
the risk of severe influenza during infancy might be associated with the underuse of 
influenza vaccination during pregnancy15,16 and among infants aged 6 months and older.17
In this prospective study,18 we aimed to assess the frequency of influenza virus infection 
among infants aged younger than 1 year who were admitted to hospital in four middle-
income countries. Here, we report the frequency of influenza virus infections identified by 
serological detection among infants who were influenza-negative by traditional molecular 
methods, describe the proportion of influenza virus infections that did not present as an 
acute respiratory illness, and report the frequency of influenza confirmed by real-time RT-
PCR (rRT-PCR) among non-ill infants enrolled during the study period from the same 
communities.
Methods
Study design and participants
Detailed methods of the Influenza and Respiratory Syncytial Virus in Infants Study (IRIS), 
including the use of a common protocol have been published previously18 (appendix pp 2–
5). The four hospitals included in the IRIS study were selected intentionally from middle-
income countries and from tropical and temperate climates (Albania, Jordan, Nicaragua, and 
the Philippines); collaborators were selected from a relatively small number of research 
organisations with experience enrolling infants in both hospital and community settings, 
following infants prospectively, and collecting both respiratory and sera specimens from 
infants.
Infants aged younger than 1 year who had been admitted to hospital were enrolled at study 
hospitals during two influenza seasons (2015–16 and 2016–17) in Albania, Jordan, and 
Nicaragua, and over a continuous 34 week period (April, 2016–December, 2016) in the 
Philippines, on the basis of previous regional influenza surveillance (appendix pp 6, 7).
All acutely ill infants admitted to hospital regardless of symptoms were identified from 
hospital admission records (including presenting complaints and preliminary diagnoses) and 
were eligible for enrolment within 24 h of admission if their family lived in the hospital 
catchment area (to facilitate follow-up) and they had been admitted to hospital within 10 
days or less of illness onset.
We also enrolled a control of non-ill infants at routine immunisation clinics and other 
settings (appendix p 6); enrolled non-ill infants were stratified by age (0–5 months vs 6–11 
months) to reflect the mixture of ages observed among infants admitted to hospital.
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The study protocol and procedures have been approved by Abt Associates (the organisation 
coordinating the study) and by Institutional Review Boards at each study site: Medical 
Ethics Committee, Ministry of Health, Tirana, Albania; Jordanian Ministry of Health 
Institutional Review Board; Comite Institucional de Revision Etica, Ministerio de Salud, 
Nicaragua; and Research Institute for Tropical Medicine Institutional Review Board. Written 
informed consent was obtained from the parents or guardians of all infants in the parent or 
guardian’s language.
Procedures
After obtaining written informed consent, parents were interviewed to document 
sociodemographic characteristics, medical history, maternal and infant vaccination history, 
and symptoms. We extracted clinician-measured temperature, respiration rate, oxygen 
saturation, and clinical discharge diagnoses from hospital records. Combined nasal and 
oropharyngeal swabs and acute sera were collected within 24 h of hospital admission. A 
convalescent blood draw was collected 3–5 weeks after enrolment.
For the enrolment of non-ill infants, screening questions confirmed that these infants were 
not currently ill and had not been acutely ill within the past 7 days with nasal congestion or 
discharge, new or worsening cough, shortness of breath, difficulty breathing, wheezing, 
fever, chills, or diarrhoea. Combined nasal and oropharyngeal swabs were collected. To 
assess whether non-ill infants developed illness symptoms after swab collection, during the 
second year of the study period, parents of non-ill infants were contacted 4–10 days after 
enrolment.
All study laboratories used singleplex rRT-PCR influenza assays and reagents, which were 
validated by the US Centers for Disease Control and Prevention (CDC) after completion of 
annual influenza proficiency panels and quality assurance testing (appendix p 3). 
Haemagglutination inhibition testing was done by Battelle Laboratory (Aberdeen, MA, 
USA) after the completion of proficiency panels (appendix p 3). Haemagglutination 
inhibition assays for the detection of antibodies against influenza A H1N1pdm09 and B 
influenza antigens were done using turkey erythrocytes, and those for the detection of 
antibodies against influenza A (H3N2) viruses were done using guinea pig erythrocytes in 
the presence of oseltamivir carboxylate to eliminate the interference by neuraminidase. For 
influenza B serology, ether treated antigens were used. Microneutralisation assays against 
influenza B viruses were done at a CDC laboratory (Atlanta, GA, USA; appendix p 2). 
Influenza serology was done on paired acute and convalescent sera against egg-grown 
viruses antigenically similar to those circulating during 2015–16 and 2016–17 influenza 
seasons: A/California/07/2009 (H1N1), A/Switzerland/9715293/2014 (H3N2), A/Hong 
Kong/ 4801/2014 (H3N2), B/Brisbane/60/2008/Victoria, and B/Phuket/3073/2013/Yamagata 
(appendix p 2).
Outcomes
The main outcome was seroconversion for influenza virus, with convalescent antibody titres 
more than or equal to four-fold higher than acute sera titres, and convalescent antibody titres 
of 40 or higher.19 For influenza A viruses, serological confirmation was defined as 
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seroconversion by haemagglutination inhibition only. Since hemagglutination inhibition for 
influenza B viruses has high sensitivity but moderate specificity for ether-treated B antigens,
20
 serological confirmation of B virus infection required achievement of seroconversion by 
both haemagglutination inhibition and by microneutralisation.
Statistical analysis
The analytic sample was limited to infants enrolled between the illness onset dates of the 
first and last infants with rRT-PCR-confirmed influenza to be admitted to hospital at each 
site. To assess possible selection and information biases, we calculated the proportion of all 
potentially eligible infants whose parent refused screening or consent and the proportion of 
infants without convalescent sera, by study year, site, age group, sex, hospital ward, 
discharge diagnosis, and rRT-PCR influenza positivity. We used multivariable logistic 
regression to examine the joint association between these covariates and study refusal or sera 
collection.
To estimate the proportion of infants with influenza, we calculated percentages and 95% CIs 
assuming a binomial distribution. We compared these percentages by infant and illness 
characteristics and by influenza type or subtype using a χ2 or Fisher’s exact test of 
association. For parent-reported infant health, values were missing for 2·2% of participants, 
and therefore we linearly imputed missing values as a function of site, year, and infant age. 
Since the study included two diagnostic indicators (molecular and serological diagnosis of 
influenza), we calculated the sensitivity and specificity of each indicator with the other 
indicator considered the so-called gold standard. For example, the sensitivity of serology 
was calculated using rRT-PCR as the gold standard whereby sensitivity was defined as the 
percentage of all rRT-PCR positives that were serologically positive; specificity of serology 
defined as the percentage of all rRT-PCR-negatives that were also serological-negatives. All 
analyses were done using SAS (version 9.4).
To summarise the frequency of influenza virus infections identified by serological detection 
among infants who were influenza-negative by traditional molecular methods, and the 
proportion of influenza virus infections that did not present as an acute respiratory illness, 
we calculated an underdetection multiplier, similar to the approach used in estimating 
population-level influenza disease burden;21 the multiplier was the ratio of influenza-
positives (by either rRT-PCR or seroconversion) with any clinical diagnosis of an acute 
illness to rRT-PCR-confirmed influenza-positives with respiratory diagnoses. We assumed 
that this multiplier would vary by site and season due to differences in participant age, 
disease presentation, and circulating influenza viruses; thus, we estimated the multiplier and 
95% CI using a beta-binomial model with maximum likelihood estimation using the SAS 
NLMIXED with BETABIN macro, whereby the ratio follows a beta distribution drawn from 
seven study site seasons (three sites with two seasons plus one season for the Philippines) 
using previously published methods21 (appendix pp 4, 5).
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Role of the funding source
The funder of the study was involved in study design, data analysis, data interpretation, and 
writing of the report. The corresponding author had full access to all the data in this study 
and had final responsibility for the decision to submit for publication.
Results
Parental consent to screening and enrolment was high across all four sites (appendix p 22); 
the parents of 3919 (97%) of 4031 infants consented to screening (range across sites 95–
99%), and 3634 (93%) of 3897 eligible infants were enrolled (range 76–99%). Consent to 
screening and enrolment were lower in the first year and at the Philippines site (appendix p 
8). After exclusion of 1376 infants enrolled outside of influenza seasons, and 315 infants 
without complete acute-convalescent pairs, 1943 infants were included in the final analytic 
sample (figure 1). In a multivariate model (appendix p 9), loss to follow-up was higher in the 
first year than the second year (p=0·050), higher at the Nicaragua and Philippines sites than 
the Albania and Philippines sites (p<0·0001), higher among infants admitted to the general 
ward than the intensive care unit (p=0·020), and higher among infants with non-respiratory 
diagnoses than respiratory diagnoses (p=0·0020), but did not differ significantly by age or 
influenza positivity (appendix p 9).
Characteristics of the 1943 infants included in the analytical sample are presented in table 1. 
The age distribution of infants varied across sites; 988 (51%) of 1943 infants were aged 0–2 
months (range across sites 32–71%), 364 (19%) were aged 3–5 months (range 14–24%), and 
591 (30%) were aged 6–11 months (range 15–49%). 1363 (70%) of 1943 infants were 
described by their parents as in very good or excellent overall health before the acute illness 
(range 56–84% across sites). 162 (8%) of 1943 infants had one or more parent-reported 
chronic medical conditions (range 5–11%), and 356 (18%) had previously been admitted to 
hospital (range 10–33%). No infants had previously received influenza vaccination; 45 
(15%) of 307 mothers in Nicaragua, three (<1%) of 664 mothers in Jordan, and no mothers 
in Albania and Philippines had received influenza vaccination during pregnancy.
1487 (76%) of 1943 infants were admitted to hospital within 4 days of illness onset (range 
69–89% across sites). Albania and Jordan had a greater volume of admissions and 
availability of intensive care; 240 (38%) of 638 enrolled infants in Albania and 251 (38%) of 
664 enrolled infants in Jordan had been admitted to the intensive care unit compared with 19 
(6%) of 307 enrolled infants in Nicaragua and 17 (5%) of 334 infants in the Philippines. 
Mean time since illness onset at admission was 3·3 days for both infants on general wards 
and infants in intensive care units. The mean length of hospital stay was 5·9 days (SD 3·2). 
Influenza antiviral drugs were not available at study hospitals.
Across sites and seasons, 152 (8%, 95% CI 6·8–9·1) of 1943 infants admitted to hospital 
were influenza-positive by rRT-PCR (range across sites 5·7–9·6%). Influenza A 
(H1N1)pdm09, influenza A (H3N2), and influenza B (Victoria lineage) viruses were 
identified at all sites (table 1).
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Acute serum was collected at a mean of 3·3 days (SD 2·0) after illness onset, and 
convalescent serum was collected at a mean of 27·8 days (SD 11·2) after onset. 
Seroconversion to at least one of the influenza A or B viruses was observed among 196 
infants. Of the 1943 infants, 94 (5%) were influenza-positive by both rRT-PCR and serology, 
58 (3%) were positive by rRT-PCR-only, and 102 (5%) were positive by serology only. 
Using rRT-PCR as the gold standard, seroconversion had a sensitivity of 62% (95% CI 54–
70; 94/152); conversely, using seroconversion as the gold standard, rRT-PCR had a 
sensitivity of 48% (41–55; 94/196; appendix p 10). Specificity was high for both serology 
(94%, 95% CI 93–95; 1689/1791) and for rRT-PCR (97%, 96–98; 1689/1747).
254 (13%) of 1943 infants were influenza-positive by either rRT-PCR or serology (table 2). 
The proportion of influenza-positive infants confirmed by rRT-PCR or serology appeared to 
vary by study site (from 9% in the Philippines to 16% in Albania) and was lower among 
infants aged 0–2 months (87 [9%] of 988 infants) than older infants (range 16–20%; 
p<0·0001). Infants described by their parents as in excellent or very good health before the 
illness were more likely to be influenza-positive (198 [15%] of 1363 infants) than those in 
good, fair, or poor health (56 [10%] of 580; p=0·010). The proportion of infants with 
influenza was highest among infants with parent-reported fever (p<0·0001), clinician-
measured temperature of 39°C or higher (p<0·0001), or a diagnosis of febrile seizures 
(p<0·0001). Influenza positivity was not associated with number of days since illness onset. 
The proportion of infants admitted to intensive care units was similar for influenza-negative 
and influenza-positive infants (28% vs 22%; p=0·072).
Of the 254 infants with confirmed influenza (according to rRT-PCR, serology, or both), 102 
(40%, 95% CI 34–46) were positive by serology only. The diagnosis was established by 
serology only, but not by rRT-PCR, in 67 (47%) of 143 infants with influenza A (H3N2), 22 
(43%) of 51 with influenza A H1N1pdm09, and 14 (25%) of 57 with influenza B(Victoria) 
viruses (table 2). The contribution of serological diagnosis increased with days since illness 
onset (p=0·039); the proportion of influenza-positive infants confirmed by serology but 
missed by rRT-PCR was lower among those admitted within 0–2 days of illness onset (28 
[30%] of 93) than among those admitted 3–4 days after onset (49 [48%] of 103). Diagnosis 
by serology only was higher among infants admitted to the intensive care unit (33 [58%] of 
57) than infants admitted to the general ward (69 [35%] of 197; p=0·0020). Diagnosis by 
serology only was also more common among infants with hypoxaemia at admission than 
those without (p=0·0030) or a clinical diagnosis of bronchiolitis or asthma (p=0·020). The 
proportion of serology-only diagnoses among all influenza-positive infants did not differ 
significantly by study site, age, demographic, health, or clinical characteristics, length of 
hospital stay, or days between illness onset and convalescent sera collection (table 2).
Of the 254 influenza-positive infants, 167 (66%) had only respiratory clinical discharge 
diagnoses, three (1%) had both respiratory and non-respiratory diagnoses, and 84 (33%) had 
only non-respiratory discharge diagnoses. The most common respiratory discharge 
diagnoses were pneumonia, bronchiolitis, and other respiratory viral disease. The most 
common non-respiratory diagnoses were sepsis, febrile seizures, dehydration, and other non-
respiratory viral diseases.
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No statistically significant differences in the proportion of influenza-positive infants with 
non-respiratory discharge diagnoses were identified by age, demographic, or health 
characteristics (table 3). However, the proportion of influenza-positive infants with non-
respiratory diagnoses differed by study site, with statistically significant differences 
identified between Albania (17 [16%] of 105 infants) and Jordan (47 [54%] of 87 infants; 
p<0·0001). This difference corresponded with differences in clinical diagnoses between 
sites: 260 (39%) of 664 infants in Jordan had a sepsis discharge diagnosis compared with 
less than 14% at the other sites (table 1). Differences observed in the proportion of 
influenza-positive infants with non-respiratory diagnoses across study sites were smaller and 
not statistically significant when stratified by age group (table 4). The proportion of infants 
with non-respiratory diagnoses was higher among those infected with influenza A (H3N2) 
than those with other influenza A or B viruses (p=0·019; table 3).
The proportion of influenza-positive infants with non-respiratory diagnoses was highest 
among infants admitted within 0–2 days of illness onset (42 [45%] 93), and was 
significantly higher than that among infants admitted 3–4 days after onset (26 [25%] of 103; 
p=0·0080; table 3). Infants with respiratory diagnoses were more likely to have cough 
(p<0·0001) and tachypnoea (p<0·0001), but less likely to have diarrhoea (p=0·0012). Among 
both respiratory and non-respiratory diagnosis groups, the proportion of infants with parent-
reported fever was similar (135 [79%] of 170 vs 60 [71%] of 84), and the proportion of 
infants with a temperature of 39°C or higher was similar (41 [24%] of 170 vs 25 [30%] of 
84). The proportion of infants admitted to intensive care units compared with general wards 
was also similar in both diagnosis groups. A substantial proportion of influenza-positive 
infants discharged with only non-respiratory diagnoses had a cough (29 [35%] of 84) or 
other respiratory symptoms (37 [45%] of 84) at admission; 17 (21%) of 84 infants had signs 
of hypoxaemia and seven (9%) of 84 infants had signs of tachypnoea.
The 98 infants with rRT-PCR confirmed influenza who had an acute respiratory illness 
discharge diagnosis accounted for only 39% of the 254 infants with any acute illness and 
influenza virus infection confirmed by either rRT-PCR or serology. This indicates that a 
focus on respiratory PCR-positive influenza disease underdetects influenza-associated 
hospital admissions among infants by a factor of 2·6 (95% CI 2·0–3·6), accounting for study 
site and season variation (table 4). The point estimate of this adjusted multiplier was higher 
for infants aged 0–5 months (3·0, 95% CI 2·1–5·0) than infants aged 6–11 months (2·0, 1·7–
2·5), but the 95% CIs overlapped. The contribution of serological and non-respiratory 
diagnoses to the total number of influenza-positive infants observed across sites is shown in 
figure 2; site-specific information is presented in the appendix (pp 18–21).
Of the 1467 infants screened for inclusion in the non-ill group, 107 (7%) were ineligible 
because of current or recent illness (onset ≤7 days) and 24 (2%) did not complete enrolment 
or their parents refused consent; of the remaining 1335 non-ill infants, 745 were enrolled 
during the influenza study period (appendix pp 11, 12). Influenza virus infection was 
detected by rRT-PCR in 21 (3%, 95% CI 1·6–4·0) of 745 infants. Similar to the acutely ill 
infants, a mixture of influenza types and subtypes were identified.
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During year 2 (between May 2016, and April 2017), the parents of 400 non-ill infants were 
contacted a mean 7·5 days (SD 2·3) after respiratory swab collection. Of the 15 infants who 
were not ill during enrolment but later tested positive for influenza by rRT-PCR, four (27%) 
subsequently developed one or more respiratory or non-respiratory illness symptoms. This 
proportion was similar to the that of non-ill rRT-PCR-negative infants (18%) who 
subsequently developed illness symptoms (appendix p 13).
Across all sites and seasons, 834 (43%) of 1943 infants met the case definition for SARI 
(cough and fever) at hospital admission (range across sites 35–53%; table 1). Of the 254 
influenza-positive infants (by rRT-PCR or serology), 157 (62%) met the case definition at 
admission; thus, 97 (38%) were non-SARI admissions (table 2). The proportion of 
influenza-positive infants admitted to hospital with non-SARI was higher among infants 
aged 0–2 months (45 [52%] of 97) than those aged 6–11 months (33 [31%] of 108; 
p=0·0027; appendix pp 15, 16). After adjusting for study site and season, assessment of rRT-
PCR-confirmed influenza presenting with SARI underdetected influenza-associated hospital 
admissions among infants by a factor of 2·6 (95% CI 2·0–3·5; appendix p 17).
Similarly, although we focused on clinical diagnoses at discharge, these diagnoses were 
consistent with admission diagnoses; most infants (1793 [92%] of 1943) remained in the 
same diagnostic category from admission to discharge (appendix p 17).
Discussion
In our multicentre, prospective study, we found that the incidence of influenza-associated 
hospital admissions among infants younger than 1 year was 2·6 times higher than would 
have been identified by rRT-PCR testing of acute respiratory illnesses. Relying on molecular 
diagnostics missed 40% of the 254 influenza virus infections identified through a 
combination of rRT-PCR and serology. Furthermore, 33% of influenza-positives were 
identified among acutely ill infants without respiratory discharge diagnoses.
Our study exclusively focused on infants and simultaneously assessed both clinical and 
diagnostic sources of underdetection. Our findings were similar to those of previous studies 
that examined these issues separately among children across a broader age range. In two 
studies of pneumonia aetiology, the number of influenza-positive infants identified only by 
serology constituted 41% of all children admitted to hospital with influenza (61 of 149 with 
A or B viruses by either rRT-PCR or serology) in US children aged younger than 18 years11 
and 47% of children admitted to hospital with influenza among children aged younger than 
5 years in Thailand.12 Studies done in emergency departments in France of children aged 0–
11 months6 and 0–35 months7 found that one-third of children identified as influenza-
positive by rRT-PCR had predominantly non-respiratory symptoms (30% and 33%, 
respectively).
The implications of our findings partly depend on how the discordance between rRT-PCR 
and serological diagnoses of influenza virus infection is interpreted. As expected, the 
proportion of infants with influenza identified by serology only was lowest among those 
admitted within 0–2 days of illness onset, when viral shedding would be highest, but even in 
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this group, about one-third of all influenza cases were rRT-PCR negative. Since testing upper 
respiratory specimens with the rRT-PCR assay is typically considered to be a highly 
sensitive and specific method, it is surprising that rRT-PCR assays were only 48% sensitive 
to seroconversions and thus missed 102 of 254 influenza cases. Such underdetection was 
documented despite our study using rRT-PCR assays in CDC-approved laboratories on 
combed nasal and oropharyngeal specimens22 collected within 4 days of illness onset for 
most infants. The use of rRT-PCR as a gold standard emerged from studies comparing the 
assay with virus culture and immunofluorescence rather than measures of immune response, 
and previous research22 suggests the sensitivity of rRT-PCR can reduce to 80% depending 
on specimen type and other differences in methodology. It is also possible that sampling 
from the upper respiratory tract might have missed virus concentrated in the lower 
respiratory tract. Further research needs to examine whether the shedding or concentration 
of virus varies by type or subtype and among infants and young children. The similar 
sensitivity (62%) of seroconversion to rRT-PCR-confirmed influenza among infants in our 
study is less surprising considering that multiple factors could have prevented 
seroconversion, including known limits in measurement sensitivity of haemagglutination 
inhibition,23,24 elevated titres among young infants from maternal antibodies, and the 
inability of young and immune-challenged infants to mount a robust antibody response to 
infection.25,26
Nosocomial influenza virus infection among children is not uncommon.27 Thus, some of the 
infants in our study who were rRT-PCR-influenza-negative at admission but who had a more 
than or equal to four-fold increase in influenza antibody titres about a month later could have 
been infected during their stay in hospital. Although the development of increased antibody 
concentrations after infection is hypothesised to take at least 2 weeks,19 it is also possible 
that some infants were infected shortly after hospital discharge. In our study, the proportion 
of infants with influenza detected by serology only was similar across study hospitals and 
was not higher among chronically ill or premature infants, those with prolonged hospital 
stays, or those with prolonged periods between acute and convalescent sera collection. 
However, the proportion of infants with influenza detected by serology only was higher 
among infants admitted to the intensive care unit than general wards, which raises the 
question of whether this could be partly due to nosocomial infections in intensive care units 
associated with increased health vulnerabilites, increased exposure to aerosol-producing 
medical procedures, or other risks. Future studies that repeatedly swab infants and test for 
influenza by rRT-PCR during and after hospital admission are needed to clarify how many of 
the serology-confirmed influenza infections were acquired after hospital admission.
It is important to note that the absence of a respiratory diagnosis by a clinician among one-
third of influenza cases does not imply the disease had no respiratory involvement. Indeed, 
almost half of the infants with only non-respiratory discharge diagnoses had cough or other 
respiratory signs and symptoms at admission. Since our study relied on clinician-recorded 
vital signs and diagnoses, it is possible that clinicians misdiagnosed some disease or were 
simply more focused on other manifestations of diseases, such as sepsis and febrile seizures. 
Since study hospitals did not have routine molecular clinical testing, clinicians rarely knew 
the underlying pathogens. Thus, across sites, clinicians referred to clinical syndromes and 
observable signs; “other viral illness” was the most commonly abstracted respiratory and 
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non-respiratory diagnosis. Clearly, future research with clinicians trained to use standard 
diagnostic procedures are needed to describe clinical features with greater detail and 
consistency. As expected, testing all acutely ill infants identified a substantial proportion of 
influenza-positive infants who would have been missed by an exclusive focus on respiratory 
diagnoses, and this was consistent across seasons and study sites. Re-examination of our 
findings using a syndromic definition, SARI, showed that rRT-PCR testing of patients with 
this condition at admission underdetected the total number of infants with influenza by 2·6 
times, which is identical to our findings using clinical discharge diagnoses.
Our sample of infants admitted to hospital with influenza is among the largest to date, 
especially outside of high-income countries. Nonetheless, future studies with even larger 
samples are needed to explore the heterogeneity we observed by age, disease severity, and 
viruses. Several findings suggest underdetection of influenza might be higher for young 
infants (aged <6 months), more severely ill infants including those admitted to intensive care 
units, and infants with influenza A (H3N2) virus infections; however, these trends were not 
statistically significant in pooled models that accounted for variations by study year and site. 
Since hospital admission can be driven by medical and social factors and admission and 
diagnostic practices can vary greatly within and across countries (eg, Albania and Jordan 
had a greater volume of admissions and availability of intensive care),4,5,28 the fact that the 
underdetection multiplier trended higher (at 4·1-fold) among the most severely ill infants 
suggests that the pooled effect across all infants is likely to be a conservative estimate of true 
effect size.
Although IRIS was designed to inform and improve interpretation of studies of influenza 
burden, our study was not designed to provide burden estimates. The extent to which our 
pooled site and study year estimates can be generalised to other countries is unclear. 
Variation in influenza incidence estimates among children even within countries during the 
same seasons is common.29,30 Thus, mathematical models that can account for multiple 
sources of heterogeneity are needed to estimate influenza burden and the potential 
preventive value of influenza vaccine programmes.21,31 Knowledge about the fraction of 
influenza virus infections among infants that might have atypical disease presentations or 
might be missed by molecular diagnostics could also be relevant to infection control 
measures in hospitals27 and to characterising trans mission dynamics using mathematical 
models.
Our study had many strengths, including the use of a common protocol, tools, and laboratory 
methods. Systematic enrolment and high participation and follow-up rates reduced the risk 
of selection biases. However, the causative role of influenza virus infections in disease 
aetiology and hospital admissions must be interpreted with caution. Our finding that 3% of 
non-ill infants enrolled simultaneously from the local communities tested positive for 
influenza by rRT-PCR is a reminder of the complexity of interpreting diagnostic results. 
Although studies of attributable risk have concluded that influenza has a relatively strong 
association with clinical illness,5,32 further research focused on infants is needed. The fact 
that during year 2 of our study (2016–17), four (27%) of 15 of non-ill infants with rRT-PCR-
influenza became ill in the days after swabbing highlights the challenges in making causal 
attributions given that some presumably non-ill infants might not be truly asymptomatic. 
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Furthermore, our study is limited by a lack of information on possible coinfections with 
other pathogens, pending further laboratory assessments. As with all influenza studies, the 
generalisability of our findings are limited by the specific influenza viruses in circulation 
during the study seasons and at specific sites; however, our study included infants infected 
with a mixture of influenza A (H1N1)pdm09, influenza A (H3N2), and influenza 
B(Victoria) viruses across all study sites. Moreover, serological methods differed for 
influenza A and influenza B viruses due to the circulating viruses and measurement best 
practices.19 For influenza A (H3N2), serological positivity was indicated by seroconversion 
to either of two circulating influenza A (H3N2) viruses. For influenza B viruses, 
seroconversion by both haemagglutination inhibition and microneutralisation was required, 
which was likely to have improved specificity but might have reduced sensitivity to 
infection. The specific laboratory methods required for this study might limit the 
generalisability of findings to a season with different circulating influenza viruses. Further 
analyses of antibody response to influenza virus infections from IRIS are planned.
If the true burden of laboratory-confirmed influenza-associated hospital admissions among 
infants is at least twice that of previous estimates, this could have implications for ongoing 
debates about the preventive value of introducing or expanding influenza vaccination 
programmes for pregnant women and infants aged 6 months or older. Justifying the 
preventive value of influenza vaccines in LMICs is especially challenging considering the 
many obstacles to implementation and competing public health priorities.13,14 Even in high-
income countries, a better understanding of the vaccine-preventable burden of severe 
influenza among infants is needed to inform future research and policy with regard to 
optimal vaccine types and strategies for pregnant women and infants aged 6 months or older.
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Research in context
Evidence before this study
Although influenza is an established cause of morbidity and mortality among infants 
worldwide, determining the burden of influenza is challenging since infants might 
present with atypical symptoms or be admitted to the hospital later in the illness, when 
they no longer test positive by molecular testing. We searched PubMed from database 
inception to Dec 31, 2018, for studies published in English using the search term 
“influenza” and filters for “human” and ages “newborn”, “infant”, or “child”; within 
these results, we applied the search terms “acute respiratory”, “burden”, “hospital”, or 
“serology”. We identified two studies of pneumonia aetiology that assessed influenza 
virus infection by both real-time RT-PCR (rRT-PCR) and serology among children 
younger than 18 years in the USA and among children younger than 5 years in Thailand. 
Both studies focused on acute respiratory disease only and data on infants were scarce. 
We identified two studies of children aged 0–11 months and aged 0–35 months done in 
emergency departments in France, which tested all acutely ill infants for influenza by 
rRT-PCR only. With the exception of the study in Thailand, all relevant previous studies 
were done in high-income countries with temperate climates.
Added value of this study
Our study is unique in its exclusive focus on infants aged younger than 1 year and the 
simultaneous assessment of both clinical and diagnostic sources of underdetection. Our 
study of infants admitted to hospital with influenza in four middle-income countries 
(including two countries with tropical climates) is among the largest to date. We found 
that molecular diagnostics missed more than one-third of influenza virus infections 
identified by a combination of rRT-PCR and serology. Furthermore, one-third of 
influenza-positive cases were identified among acutely ill infants without respiratory 
clinical discharge codes. To our knowledge, this is the first study to estimate the 
magnitude of influenza underdetection in this population using a broad case definition 
and applying both molecular and serological diagnostic methods.
Implications of all the available evidence
The global burden of severe influenza would be substantially underestimated if the true 
incidence of laboratory-confirmed influenza-associated hospital admissions among 
infants is at least twice that of previous estimates using existing respiratory surveillance 
platforms. This incremental increase in burden estimates might expand estimates of the 
preventive value of maternal and infant influenza vaccination programmes, which is 
especially relevant to low-income and-middle-income countries considering the many 
obstacles to implementation and competing health priorities. Even in high-income 
countries, a better understanding of the vaccine-preventable burden of severe influenza 
among infants is needed to inform future research and policy with regard to optimal 
vaccine types and strategies for pregnant women and infants aged 6 months and older. 
Further research is warranted to examine the extent to which underdetection of influenza 
varies by age groups, disease severity, and virus type or subtype.
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Figure 1: 
Study profile
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Figure 2: Number of influenza-positive infants by diagnostic method and clinical discharge 
diagnosis across study sites
rRT-PCR=real-time RT-PCR.
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Table 3:
Influenza virus positives by clinician discharge diagnosis and proportion of all influenza-positive infants with 
non-respiratory diagnoses
Respiratory or mixed 
diagnoses, n (%)
Non-respiratory 
diagnosis, n (%)
Proportion of influenza-
positive cases with non-
respiratory diagnosis, % 
(95% CI)*
p value†
Influenza-positive infants (n=254) 170 (67%) 84 (33%) 33 (27 to 39) ··
Dichotomous age, months
 0–5 (n=146) 93 (64%) 53 (36%) 36 (29 to 44) 0·20
 6–11 (n=108) 77 (71%) 31 (29%) 29 (20 to 37) ··
Catergorical age, months
 0–2 (n=87) 51 (59%) 36 (41%) 41 (31 to 52) 0·091
 3–5 (n=59) 42 (71%) 17 (29%) 29 (17 to 40) ··
 6–8 (n=65) 50 (77%) 15 (23%) 23 (13 to 33) ··
 9–11 (n=43) 27 (63%) 16 (37%) 37 (23 to 52) ··
Enrolment year
 2015–16 (n=122) 86 (70%) 36 (30%) 30 (21 to 38) 0·25
 2016–17 (n=132) 84 (64%) 48 (36%) 36 (28 to 45) ··
Enrolment site
 Albania (n=105) 88 (84%) 17 (16%) 16 (9 to 23) <0·0001
 Jordan (n=87) 40 (46%) 47 (54%) 54 (44 to 64) ··
 Nicaragua (n=31) 18 (58%) 13 (42%) 42 (25 to 59) ··
 Philippines (n=31) 24 (77%) 7 (23%) 23 (8 to 37) ··
Sex
 Boys (n=142) 97 (68%) 45 (32%) 32 (24 to 39) 0·60
 Girls (n=112) 73 (65%) 39 (35%) 35 (26 to 44) ··
Clinical preterm and gestational age 
<37 weeks‡ (n=17)
13 (76%) 4 (24%) 24 (3 to 44) 0·39
Chronic medical condition(s)§ (n=14) 12 (86%) 2 (14%) 14 (−4 to 33) 0·11
Previous hospital admission (n=48) 34 (71%) 14 (29%) 29 (16 to 42) 0·52
Parent reported infant health¶
 Poor or fair (n=18) 13 (72%) 5 (28%) 28 (7 to 48) 0·79
 Good (n=38) 26 (68%) 12 (32%) 32 (17 to 46) ··
 Excellent or very good (n=198) 131 (66%) 67 (34%) 34 (27 to 40) ··
Time since illness onset, days
 0–2 days (n=93) 51 (55%) 42 (45%) 45 (35 to 55) 0·0075
 3–4 days (n=103) 77 (75%) 26 (25%) 25 (17 to 34) ··
 5–10 days (n=58) 42 (72%) 16 (28%) 28 (16 to 39) ··
 Mean (SD) 3·5 (1·8) 3·0 (2·0) 0·11
SARI status‖
 No SARI (n=97) 38 (39%) 59 (61%) 61 (51 to 71) <0·0001
 Met SARI definition (n=157) 132 (84%) 25 (16%) 16 (10 to 22) ··
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Respiratory or mixed 
diagnoses, n (%)
Non-respiratory 
diagnosis, n (%)
Proportion of influenza-
positive cases with non-
respiratory diagnosis, % 
(95% CI)*
p value†
Hospital department**
 General ward (n=197) 133 (68%) 64 (32%) 32 (26 to 39) 0·71
 Intensive care unit (n=57) 37 (65%) 20 (35%) 35 (23 to 47) ··
Antibiotic treatment after hospital admission
 No (n=35) 20 (57%) 15 (43%) 43 (26 to 59) 0·19
 Yes (n=219) 150 (68%) 69 (32%) 32 (25 to 38) ··
Mean length of hospital stay, days 
(SD)
6·2 (4·0) 5·3 (3·7) 0·75
Meant time from illness onset to 
convalescence, days (SD)
30·1 (9·5) 27·2 (7·5) 0·47
Parent reported symptoms
 Cough (n=184) 155 (84%) 29 (16%) 16 (10 to 21) <0·0001
 Other respiratory symptoms (n=193) 156 (81%) 37 (19%) 19 (14 to 25) <0·0001
 Fever, felt hot, or chills (n=195) 135 (69%) 60 (31%) 31 (24 to 37) 0·16
 Vomiting (n=64) 41 (64%) 23 (36%) 36 (24 to 48) 0·57
 Diarrhoea (n=57) 28 (49%) 29 (51%) 51 (38 to 64) 0·0012
Vital signs
 High temperature (≥39°C; n=66) 41 (62%) 25 (38%) 38 (26 to 50) 0·065
 Hypoxaemia†† (n=75) 58 (77%) 17 (23%) 23 (13 to 32) 0·38
 Tachypnoea‡‡ (n=55) 48 (87%) 7 (13%) 13 (4 to 22) 0·0026
Respiratory diagnoses
 Acute respiratory distress syndrome 
(n=0)
0 0 ·· NA
 Bronchiolitis or asthma (n=56) 56 (100%) 0 ·· <0·0001
 Pertussis-like syndrome (n=5) 5 (100%) 0 ·· 0·11
 Pneumonia (n=89) 87 (98%) 2 (2%) 2·2 (−1 to 5·3) <0·0001
 Viral or other (n=38) 33 (87%) 5 (13%) 13 (2 to 24) 0·0021
Non-respiratory diagnoses
 Dehydration (n=11) 1 (9%) 10 (91%) 91 (74 to 108) <0·0001
 Febrile seizures (n=16) 6 (38%) 10 (62%) 63 (39 to 86) 0·0097
 Meningitis (n=4) 1 (25%) 3 (75%) 75 (33 to 117) 0·11
 Sepsis (n=38) 12 (32%) 26 (68%) 68 (54 to 83) <0·0001
 Urinary tract infection (n=6) 0 6 (100%) 100 (100 to 100) 0·0012
 Viral or other (n=61) 16 (26%) 45 (74%) 74 (63 to 85) <0·0001
Influenza status by rRT-PCR or serology
 A Influenza positive (n=198) 127 (64%) 71 (36%) 36 (29 to 43) 0·075
 A(H1N1)pdm09 positive (n=51) 36 (71%) 15 (29%) 29 (17 to 42) 0·53
 A(H3N2) positive (n=143) 87 (61%) 56 (39%) 39 (31 to 47) 0·019
 B Influenza positives (n=62) 47 (76%) 15 (24%) 24 (14 to 35) 0·088
 B (Victoria) positive (n=57) 42 (74%) 15 (26%) 26 (15 to38) 0·21
Data are n or n/N (%), unless otherwise specified. SARI=severe acute respiratory infection. rRT-PCR=real-time RT-PCR.
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*CIs calculated using binomial method.
†χ2, Fisher’s exact test, or one-way ANOVA test of association between each variable and respiratory diagnosis, among all influenza-positive 
samples.
‡
Infants were considered full term if they were born at known gestational age ≥37 weeks; infants born with a calculated gestational age of <37 
weeks were not considered preterm if parents did not report them as such in questionnaire.
§40 infants had no chronic conditions reported because their status was classified as unknown or their parents refused to provide this information.
¶Some values imputed to complete dataset, using a linear combination of other variables (infant age, country, study year and depravation).
‖An acute respiratory infection with history of fever or measured fever of ≥38°C and cough with onset within the last 10 days that required hospital 
admission.
**General ward includes infants who required treatment in the intensive care unit but were placed in a general ward.
††Oxygen saturation <93%.
‡‡
For infants aged 0–2 months, respiration rate >60 breaths per min; for infants aged 2–12 months, respiration rate >50 breaths per min.
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Table 4:
All influenza virus positives by respiratory versus non-respiratory discharge diagnosis and underdetection 
multiplier by age
All rRT-PCR positives (n=152) Positive by serology only (n=102) Underdetection 
multiplier*, X (95% CI)Respiratory or 
mixed, n (%)
Non- respiratory, 
n (%)
Respiratory or 
mixed, n (%)
Non-respiratory, 
n (%)
Influenza-positive 
infants (n=254)
98 (39%) 54 (21%) 72 (28%) 30 (12%) 2·6 (2·0–3·6)†
Age, months
 0–5 (n=146) 45 (31%) 35 (24%) 48 (33%) 18 (12%) 3·0 (2·1–5·0)†
 6–11 (n=108) 53 (49%) 19 (18%) 24 (22%) 12 (11%) 2·0 (1·7–2·5)†
Hospital department
 General ward 
(n=197)
84 (43%) 44 (22%) 49 (25%) 20 (10%) 2·4 (1·8–3·4)†
 Intensive care unit 
(n=57)
14 (25%) 10 (18%) 23 (40%) 10 (18%) 4·1 (2·7–9·1)†
Influenza subtype
 A(H1N1) pdm09 
positive (n=51)
22 (43%) 7 (14%) 14 (27%) 8 (16%) 2·3 (1·6–4·0)†
 A(H3N2) positive 
(n=143)
39 (27%) 37 (26%) 48 (34%) 19 (13%) 4·0 (2·6–8·4)†
 Blq B (Victoria) 
positive (n=57)
32 (56%) 12 (21%) 10 (18%) 3 (5%) 1·8 (1·4–2·3)†
Enrolment site
 Albania (n=105) 53 (50%) 8 (8%) 35 (33%) 9 (9%) 2·0 (1·5–2·8)
 Jordan (n=87) 19 (22%) 33 (38%) 21 (24%) 14 (16%) 4·6 (3·3–7·7)
 Nicaragua (n=31) 12 (39%) 8 (26%) 6 (19%) 5 (16%) 2·6 (1·8–4·8)
 Philippines 
(n=31)
14 (45%) 5 (16%) 10 (32%) 2 (6%) 2·2 (1·6–3·6)
Age 0–5 months by site
 Albania (n=53) 23 (43%) 2 (4%) 23 (43%) 5 (9%) 2·2 (1·5–4·2)
 Jordan (n=63) 11 (17%) 25 (40%) 16 (25%) 11 (17%) 5·7 (3·7–12·7)
 Nicaragua (n=20) 8 (40%) 5 (25%) 5 (25%) 2 (10%) 2·3 (1·4–10·8)
 Philippines 
(n=10)
3 (30%) 3 (30%) 4 (40%) 0 3·3 (1·7–57·4)
Age 6–11 months by site
 Albania (n=52) 30 (58%) 6 (12%) 12 (23%) 4 (8%) 1·7 (1·4–2·3)
 Jordan (n=24) 8 (33%) 8 (33%) 5 (21%) 3 (13%) 3·0 (1·9–7·5)
 Nicaragua (n=11) 4 (36%) 3 (27%) 1 (9%) 3 (27%) 2·8 (1·5–12·6)
 Philippines 
(n=21)
11 (52%) 2 (10%) 6 (29%) 2 (10%) 1·9 (1·4–3·2)
Estimates pooled by year unless otherwise indicated. Some percentages do not equal 100 because of rounding.
*
Pooled estimates calculated using beta binomial models with maximum likelihood estimation.
†
Pooled by site and year.
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